Mistaken Side Effect Fears Stop Women From Breast Cancer Drug

Mistaken Side Effect Fears Stop Women From Breast Cancer Drug

Many women who are at high risk of developing breast cancer are not taking the drug tamoxifen – which has been shown to reduce that risk – because they mistake symptoms of early menopause for side effects of the drug.

A study that has been ongoing since 1992, the International Breast Intervention Study (IBIS-I) has demonstrated that the preventative benefits of tamoxifen last for 20 years or more. Yet new data indicates that only 1 in 6 women at high risk for developing breast cancer — those with a family history of the cancer — take tamoxifen, and not all of them that do manage to take it consistently for 5 years as recommended.

Prior research has found that tamoxifen can reduce the likelihood of developing breast cancer by at least 30% in high-risk women.

In the new study, published in the Journal of Clinical Oncology, researchers examined data on 3,823 women who took part in IBIS-1 and received either tamoxifen or a placebo for 5 years.

About 65% of women taking tamoxifen stuck with it for 5 years, compared to 74% of those on placebo. Side effects reported included nausea or vomiting, headaches and gynecological issues.

Of women who reported nausea or vomiting, around 40% quit their treatment, whether they were receiving tamoxifen or a placebo. Researchers found that many women on a placebo experienced nausea, sickness and hot flushes, symptoms also associated with menopause. This leads them to believe many women are incorrectly blaming tamoxifen for side effects that are really part of menopause.

“This suggests that women may be attributing normally-occurring, age-related symptoms, such as those experienced around the time of menopause, to their medication instead,” co-author Ivana Sestak, PhD, of Queen Mary University of London, said in a statement.

“Communicating accurate information on side effects to patients, and highlighting that some naturally-occurring symptoms may occur during the course of therapy, could be a useful approach in encouraging adherence,” she added.

Tamoxifen does have some more serious side effects such as an increased risk of blood clots, strokes and endometrial and uterine cancers, though these are relatively rare.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement